Cargando…
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group
Effective systemic therapies suppress toxic light chain production leading to an increased proportion of patients with light chain (AL) amyloidosis who survive longer albeit with end-stage renal disease. There is a critical need to identify patients in this population who benefit from renal transpla...
Autores principales: | Havasi, Andrea, Heybeli, Cihan, Leung, Nelson, Angel-Korman, Avital, Sanchorawala, Vaishali, Cohen, Oliver, Wechalekar, Ashutosh, Bridoux, Frank, Jaffer, Insara, Gutgarts, Victoria, Hassoun, Hani, Levinson, Maya, Rosenbaum, Cara, Milani, Paolo, Palladini, Giovanni, Merlini, Giampaolo, Hegenbart, Ute, Schönland, Stefan, Veelken, Kaya, Pogrebinsky, Alexander, Doros, Gheorghe, Landau, Heather |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388492/ https://www.ncbi.nlm.nih.gov/pubmed/35982035 http://dx.doi.org/10.1038/s41408-022-00714-5 |
Ejemplares similares
-
Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis
por: Mendelson, Lisa, et al.
Publicado: (2022) -
Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020) -
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
por: Leung, Nelson, et al.
Publicado: (2018) -
Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
por: Leung, Nelson, et al.
Publicado: (2018) -
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
por: Gertz, Morie A., et al.
Publicado: (2023)